8-K: Tivic Health Reports Improved Q1 2024 Financials and Vagus Nerve Stimulation Progress

Tivic Health announced its Q1 2024 financial results, showing improved gross profit and reduced operating loss, alongside progress in their non-invasive vagus nerve stimulation program.

Summary

• Tivic Health reported a revenue of $334 thousand for Q1 2024, a decrease of 11% compared to $376 thousand in Q1 2023 due to reduced unit sales volume.
• Gross profit increased by 48% to $167 thousand in Q1 2024, up from $113 thousand in Q1 2023, with gross margin improving to 50% from 30%.
• Operating expenses decreased by 26% to $1.6 million in Q1 2024, compared to $2.2 million in Q1 2023.
• The net loss for Q1 2024 was $1.5 million, a 29% improvement from the $2.1 million loss in Q1 2023.
• The company completed enrollment in their clinical study for non-invasive vagus nerve stimulation (nVNS) and demonstrated significant changes in heart rate variability and autonomic nervous system activity.
• Tivic Health raised $4.0 million in gross proceeds through a public offering of shares and warrants, resulting in net proceeds of approximately $3.5 million.
• As of May 14, 2024, the company had approximately $4.7 million in cash and cash equivalents and maintained a no debt balance sheet.

Sentiment

Score: 7

Explanation: The document presents a generally positive outlook with significant improvements in gross profit and operating loss, along with promising clinical results. However, the decrease in revenue and ongoing net loss temper the overall sentiment.

Positives

• Gross profit increased significantly by 48% year-over-year.
• Operating expenses decreased by 26% year-over-year.
• Net loss improved by 29% year-over-year.
• The company successfully completed enrollment in their nVNS clinical study.
• Tivic Health demonstrated positive results with their nVNS system, showing changes in heart rate variability and autonomic nervous system activity.
• The company launched an improved version of their ClearUP device.
• Tivic Health secured a distribution agreement with a major medical equipment distributor.
• The company raised $3.5 million in net proceeds from a public offering.

Negatives

• Revenue decreased by 11% year-over-year due to reduced unit sales volume.
• The company still reported a net loss of $1.5 million for the quarter.
• Cash and cash equivalents decreased from $3.4 million at the end of 2023 to $1.7 million at the end of Q1 2024 before the capital raise.

Risks

• The company's financial condition is subject to market and economic conditions.
• Supply chain constraints and macroeconomic factors, including inflation, could impact the business.
• The company's ability to raise additional capital on favorable terms is not guaranteed.
• Changes in regulatory requirements could affect the company's operations.
• Unexpected costs or expenses could reduce Tivic's capital resources.

Future Outlook

The company anticipates further development and commercialization of its bioelectronic medicine technologies, particularly in the area of non-invasive vagus nerve stimulation, and plans to discuss this program further with investors.

Management Comments

• Jennifer Ernst, CEO of Tivic Health, stated that Q1 2024 and the weeks thereafter represent a critical juncture in Tivic's advancement in the bioelectronics field.
• The CEO noted that the company increased gross profit and reduced operating loss year-over-year by stabilizing cost of goods, improving technology, simplifying sales channels, and focusing marketing strategies.
• The CEO also highlighted the completion of enrollment in their clinical research at the Feinstein Institutes for Medical Research and the demonstration of substantive changes in heart rate variability with their nVNS system.

Industry Context

The announcement highlights Tivic Health's progress in the growing field of bioelectronic medicine, particularly in non-invasive neuromodulation. The company's focus on vagus nerve stimulation aligns with increasing interest in this area for treating various conditions in neurology, psychiatry, and cardiology.

Comparison to Industry Standards

• Tivic's 48% increase in gross profit is a positive sign, indicating improved efficiency in production and sales, which is a key metric for early-stage medical device companies.
• The 26% reduction in operating expenses suggests effective cost management, which is crucial for companies that are not yet profitable.
• The successful completion of the nVNS clinical study and the demonstration of significant physiological changes are important milestones, as clinical validation is critical for gaining market acceptance and regulatory approvals.
• Compared to other bioelectronic medicine companies, Tivic's focus on non-invasive vagus nerve stimulation is a differentiating factor, as many competitors focus on implantable devices.
• The $4.0 million capital raise is a necessary step for funding ongoing research and development, as well as commercialization efforts, which is typical for companies in this sector.

Stakeholder Impact

• Shareholders may view the improved financial metrics and clinical progress positively.
• Employees may be encouraged by the company's advancements and financial stability.
• Customers may benefit from the improved ClearUP 2.0 device and potential new therapies.
• Suppliers may see increased demand for components and materials.
• Creditors may have increased confidence in the company's ability to meet its obligations.

Next Steps

• The company will file its MD&A and consolidated financial statements for the quarter ended March 31, 2024, with the SEC on May 15, 2024.
• Management will host a webcast/conference call on May 15, 2024, to discuss the Q1 2024 financial results and provide a business update.
• The company plans to further develop and commercialize its bioelectronic medicine technologies, particularly in the area of non-invasive vagus nerve stimulation.

Key Dates

Keywords

bioelectronic medicine, vagus nerve stimulation, non-invasive, ClearUP, financial results, clinical study, medical device, neurology, cardiology, psychiatry